Pfizer Doubles Down In RSV By Buying ReViral

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Pfizer will acquire ReViral for up to $525m, adding a Phase II antiviral for respiratory syncytial virus (RSV), complementing its own work to develop a vaccine.

poker chips
Pfizer is placing more bets in RSV • Source: Alamy

Pfizer Inc. is expanding its investment in the competitive race to bring treatments to market for respiratory syncytial virus (RSV), with the acquisition of ReViral Ltd. for up to $525m, announced on 7 April. Pfizer already is in late-stage development with a potential vaccine for RSV but will gain a Phase II antiviral that could be a treatment for both children and adults with the respiratory virus, which can cause hospitalization and death.

The strategy mirrors the approach Pfizer has pursued in COVID-19, with the development of the vaccine Comirnaty and the oral...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.